Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INMD InMode	$15.16 -0.4%	$14.33	$13.14 ▼ $19.85	$957.95M	1.95	1.23 million shs	595,953 shs
MDXG MiMedx Group	$6.29 +0.9%	$6.50	$5.47 ▼ $10.14	$928.29M	1.76	675,108 shs	319,320 shs
NVRO Nevro	$5.85 +0.1%	$5.85	$3.17 ▼ $10.37	$224.32M	0.81	800,223 shs	753,602 shs
SIBN SiBone	$18.46 +0.2%	$17.82	$11.70 ▼ $20.05	$786.77M	0.93	395,377 shs	288,621 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INMD InMode	0.00%	+6.80%	+7.03%	-1.59%	-12.75%
MDXG MiMedx Group	0.00%	+5.81%	-3.16%	-11.35%	-7.44%
NVRO Nevro	0.00%	0.00%	0.00%	0.00%	-32.10%
SIBN SiBone	0.00%	+0.16%	-2.33%	+37.05%	+42.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INMD InMode	3.3331 of 5 stars	3.1	3.0	0.0	3.1	1.7	1.9
MDXG MiMedx Group	3.4324 of 5 stars	3.5	3.0	0.0	0.6	3.3	1.9
NVRO Nevro	0.1712 of 5 stars	1.0	0.0	0.0	0.0	1.7	0.6
SIBN SiBone	4.1495 of 5 stars	2.5	5.0	3.3	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INMD InMode	2.13	Hold	$18.54	22.35% Upside
MDXG MiMedx Group	3.00	Buy	$12.50	98.89% Upside
NVRO Nevro	1.92	Reduce	$5.36	-8.29% Downside
SIBN SiBone	3.00	Buy	$22.50	21.89% Upside

Current Analyst Ratings Breakdown

Latest NVRO, INMD, MDXG, and SIBN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/6/2025	SIBN SiBone	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/6/2025	SIBN SiBone	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/6/2025	SIBN SiBone	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/30/2025	INMD InMode	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $24.00
4/29/2025	INMD InMode	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$19.00 ➝ $16.25
4/29/2025	INMD InMode	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $15.00
4/29/2025	INMD InMode	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/28/2025	INMD InMode	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/28/2025	INMD InMode	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$22.00 ➝ $16.00
4/28/2025	INMD InMode	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/14/2025	INMD InMode	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$16.00 ➝ $15.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INMD InMode	$394.82M	2.43	$1.82 per share	8.31	$10.12 per share	1.50
MDXG MiMedx Group	$348.88M	2.66	$0.33 per share	19.14	$1.31 per share	4.80
NVRO Nevro	$408.52M	0.55	N/A	N/A	$8.10 per share	0.72
SIBN SiBone	$167.18M	4.71	N/A	N/A	$3.98 per share	4.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INMD InMode	$181.27M	$2.33	6.50	8.33	N/A	44.79%	17.17%	15.20%	7/30/2025 (Estimated)
MDXG MiMedx Group	$42.42M	$0.27	23.28	19.64	N/A	11.40%	22.70%	16.77%	7/30/2025 (Estimated)
NVRO Nevro	-$92.21M	-$3.05	N/A	N/A	N/A	-16.54%	-23.52%	-10.83%	8/4/2025 (Estimated)
SIBN SiBone	-$30.91M	-$0.64	N/A	N/A	N/A	-15.03%	-16.00%	-11.69%	8/4/2025 (Estimated)

Latest NVRO, INMD, MDXG, and SIBN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	MDXG MiMedx Group	$0.06	N/A	N/A	N/A	$90.79 million	N/A
5/5/2025	Q1 2025	SIBN SiBone	-$0.24	-$0.15	+$0.09	-$0.15	$45.13 million	$47.29 million
4/30/2025	Q1 2025	MDXG MiMedx Group	$0.06	$0.06	N/A	$0.05	$86.32 million	$88.21 million
4/28/2025	Q1 2025	INMD InMode	$0.45	$0.31	-$0.14	$0.26	$82.21 million	$77.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INMD InMode	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
NVRO Nevro	N/A	N/A	N/A	N/A	N/A
SIBN SiBone	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INMD InMode	N/A	8.73	7.86
MDXG MiMedx Group	0.09	4.70	4.13
NVRO Nevro	0.67	5.02	3.76
SIBN SiBone	0.21	8.53	7.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INMD InMode	68.04%
MDXG MiMedx Group	79.15%
NVRO Nevro	95.52%
SIBN SiBone	98.11%

Insider Ownership

Company	Insider Ownership
INMD InMode	6.92%
MDXG MiMedx Group	1.70%
NVRO Nevro	3.20%
SIBN SiBone	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INMD InMode	480	63.21 million	58.84 million	Optionable
MDXG MiMedx Group	870	147.70 million	145.19 million	Optionable
NVRO Nevro	1,090	38.37 million	36.27 million	Optionable
SIBN SiBone	350	42.62 million	40.95 million	Optionable

NVRO, INMD, MDXG, and SIBN Headlines

Recent News About These Companies

Lisanti Capital Growth LLC Makes New Investment in SiBone (NASDAQ:SIBN)

June 29, 2025 | marketbeat.com

SI-BONE (NASDAQ:SIBN) Sees Unusually-High Trading Volume - Here's Why

June 13, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on SI-BONE FY2026 Earnings

June 11, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Sells 308,333 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

June 10, 2025 | marketbeat.com

Charter Oak Capital Management LLC Makes New $337,000 Investment in SI-BONE, Inc. (NASDAQ:SIBN)

June 8, 2025 | marketbeat.com

SI-BONE to Truist Securities MedTech Conference on June 17, 2025

June 4, 2025 | globenewswire.com

SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025

May 28, 2025 | globenewswire.com

SI-BONE’s SWOT analysis: stock poised for growth amid market expansion

May 27, 2025 | investing.com

Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?

May 26, 2025 | zacks.com

Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 2,424 Shares of Stock

May 21, 2025 | insidertrades.com

Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 4,937 Shares of Stock

May 16, 2025 | insidertrades.com

4 Recent Earnings Winners Riding Fresh Momentum in May (SIBN)

...

May 14, 2025 | marketbeat.com

What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?

May 13, 2025 | zacks.com

Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

May 9, 2025 | finance.yahoo.com

Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet

May 8, 2025 | zacks.com

SI-BONE Inc. Q1 Loss Decreases, Beats Estimates

May 7, 2025 | nasdaq.com

SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025

May 6, 2025 | globenewswire.com

SI-BONE, Inc. Reports Strong Q1 2025 Growth

May 5, 2025 | tipranks.com

SI-BONE, Inc. (SIBN) Q1 2025 Earnings Call Transcript

May 5, 2025 | seekingalpha.com

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

May 5, 2025 | zacks.com

SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance

May 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVRO, INMD, MDXG, and SIBN Company Descriptions

InMode NASDAQ:INMD

$15.16 -0.06 (-0.36%)

Closing price 07/3/2025 03:31 PM Eastern

Extended Trading

$15.16 +0.01 (+0.03%)

As of 07/3/2025 04:57 PM Eastern

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

MiMedx Group NASDAQ:MDXG

$6.28 +0.06 (+0.88%)

Closing price 07/3/2025 03:00 PM Eastern

Extended Trading

$6.16 -0.12 (-1.91%)

As of 07/3/2025 04:20 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Nevro NYSE:NVRO

$5.85 +0.01 (+0.10%)

Closing price 04/2/2025

Extended Trading

$5.85 0.00 (0.00%)

As of 04/2/2025 07:56 PM Eastern

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

SiBone NASDAQ:SIBN

$18.46 +0.03 (+0.16%)

As of 07/3/2025 01:04 PM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time